TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
Brief Summary: RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.

PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
D: Arm Label: Vitamin D3 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Vitamin D3 600 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 4000 IU | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 600 IU

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation (AF)
Brief Summary: The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.


Options:
A: Arm Label: AF ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Atrial Fibrillation ablation | Arm Label: Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone | Intervention Type: PROCEDURE; Name: Atrial Fibrillation ablation; Assigned to Arm(s): AF ablation | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Amiodarone
B: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: CELIVARONE (SSR149744C); Assigned to Arm(s): N/A
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Amiodarone 600mg/200mg od; Type: ACTIVE_COMPARATOR; Interventions: Drug: amiodarone | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: amiodarone; Assigned to Arm(s): Amiodarone 600mg/200mg od

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomised, Double-blind, Cross-over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort ®(Budesonide/Formoterol) 320/9μg One Inhalation Twice Daily Compared With Placebo and Oxis® 9μg One Inhalation Twice Daily in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Arm Label: Symbicort then Formoterol then Placebo; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Arm Label: Formoterol then Symbicort then Placebo; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Arm Label: Placebo then Formoterol then Symbicort; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Intervention Type: DRUG; Name: budesonide/formoterol Turbuhaler 320/9µg; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo | Intervention Type: DRUG; Name: formoterol Turbuhaler 9µg; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo
C: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
D: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.
Brief Summary: This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.
Brief Summary: This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.
Brief Summary: This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
C: Arm Label: pregabalin CR 330 mg; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: pregabalin CR 165 mg; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 165 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 165 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults With HIV Infection Being Treated With Antiretroviral Therapy Containing Tenofovir Compared to Those Being Treated With Antiretroviral Therapy Not Containing Tenofovir
Brief Summary: The purpose of this study is to test the effects of Vitamin D on renal phosphate and bone loss, which are common in HIV infected adolescents and young adults being treated with tenofovir.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebos | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Other: Placebos | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Other: Placebos | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Fenofibrate, Other: Placebos | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Drug: Fenofibrate | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): 3, 5 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 4, 5 | Intervention Type: OTHER; Name: Placebos; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: "Strong vitamin D"; Type: EXPERIMENTAL; Interventions: Drug: Rocaltrol, Drug: Vitamin D, Drug: Calcium | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D, Drug: Calcium | Arm Label: Calcium; Type: PLACEBO_COMPARATOR; Interventions: Drug: Calcium | Intervention Type: DRUG; Name: Rocaltrol; Assigned to Arm(s): "Strong vitamin D" | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): "Strong vitamin D", Vitamin D | Intervention Type: DRUG; Name: Calcium; Assigned to Arm(s): "Strong vitamin D", Calcium, Vitamin D
C: Intervention Type: DRUG; Name: multivitamin; Assigned to Arm(s): N/A
D: Arm Label: A: tenofovir/vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D supplement | Arm Label: B: tenofovir/placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: C: no tenofovir/vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D supplement | Arm Label: D: no tenofovir/placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D supplement; Assigned to Arm(s): A: tenofovir/vitamin D, C: no tenofovir/vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B: tenofovir/placebo, D: no tenofovir/placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Lactbacillus GG on Wheeze and Allergic Sensitization in Infants at Risk
Brief Summary: Given that asthma results from a complex interaction between genetic susceptibility and environmental factors and rates of childhood asthma are increasing, primary prevention has to focus on modifiable aspects such as nutrition. There a implications from epidemiology that food supplementation with probiotics given to atopic mothers in pregnancy and during lactation can prevent the development allergies in the offspring. Children with atopic dermatitis are at increased risk (up to 80%) of developing persistent respiratory tract disease. Our trial examined whether probiotics are able to prevent allergic sensitization and allergic asthma when given to 6-24 month old infants at an increased risk of allergies.


Options:
A: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
B: Intervention Type: DRUG; Name: Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu); Assigned to Arm(s): N/A
C: Arm Label: LP GMNL-133 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 capsule | Arm Label: LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LF GM-090 capsule | Arm Label: LP GMNL-133+LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 +LF GM-090 capsule | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 capsule; Assigned to Arm(s): LP GMNL-133 group | Intervention Type: BIOLOGICAL; Name: LF GM-090 capsule; Assigned to Arm(s): LF GM-090 group | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 +LF GM-090 capsule; Assigned to Arm(s): LP GMNL-133+LF GM-090 group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Infants drink formula added with LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Casein hydrolysate added with LGG | Arm Label: Infants drink casein hydrolysate without LGG; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Infants drink casein hydrolysate without LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Casein hydrolysate added with LGG; Assigned to Arm(s): Infants drink formula added with LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Infants drink casein hydrolysate without LGG; Assigned to Arm(s): Infants drink casein hydrolysate without LGG

Answer: B